arrow
C

Cirino Botta

University of Palermo
H指数:38
被引数:4,009

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus

优化三药类暴露复发/难治性多发性骨髓瘤患者中BCMA靶向T细胞结合疗法的实际应用:一项意大利改良德尔菲共识

Cancers
IF4.4
2026-08-110
OA
Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions

NK和肿瘤细胞状态在多发性骨髓瘤进展中的协同进化,从前体条件开始

2026-05-220
OA
Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy

与Teclistamab相比,Elranatamab在意大利用于管理三药类暴露的复发/难治性多发性骨髓瘤患者的成本效益。

Cancers
IF4.4
2026-04-030
OAAI
Immune-Based Biomarkers as Predictors of Mortality in ECMO Therapy for Severe COVID-19 ARDS: Insights from a Retrospective Study

基于免疫的生物标志物作为严重COVID-19 ARDS患者ECMO治疗中死亡率的预测因子:一项回顾性研究的见解

2025-12-310
OAAI
Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study

新诊断前列腺癌患者中单克隆丙种球蛋白病的患病率:一项相关性视角的观察性研究

2025-11-270
OAAI
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

更正:连续或固定剂量卡非佐米、来那度胺和地塞米松(KRD)用于复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络(EMN)意大利多中心回顾性真实世界调查的长期随访结果

2025-11-130
OAAI
Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study

基于IMiD/aCD38方案的多发性骨髓瘤患者血栓风险评估的炎症生物标志物:一项前瞻性观察研究的见解

2025-10-310
OAAI
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

连续或固定剂量卡非佐米、来那度胺和地塞米松 (KRd) 治疗复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络 (EMN) 意大利 多中心、回顾性真实世界研究的长-term随访

2025-10-070
OA
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies

一项针对接受二线治疗的难治/复发功能性高风险多发性骨髓瘤患者的意大利真实世界多中心研究

2025-09-100
OAAI
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study

伊沙图昔单抗、泊马度胺和地塞米松 (IsaPd) 在达雷妥尤单抗难治性多发性骨髓瘤患者中的疗效和预后指标: 一项多中心真实世界研究

2025-02-030
OAAI
BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell features

BNT162b2 COVID-19疫苗接种可诱导具有自然杀伤细胞特征的CD16+CD8+ T细胞扩增

2025-01-310
OAAI
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience
2024-10-310
OAAI
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
2023-09-206
OAAI
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

用于预测遗传异质性多发性骨髓瘤的免疫治疗结果和免疫逃避机制的临床前模型

2023-03-1628
OAAI
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
2022-09-146
OAAI
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

循环肿瘤和免疫细胞用于阴燃性多发性骨髓瘤的微创危险分层

2022-09-0828
OA